136 related articles for article (PubMed ID: 35869818)
1. Correlation of p53 immunohistochemistry with TP53 mutational status and overall survival in newly diagnosed acute myeloid leukaemia.
Fitzpatrick MJ; Boiocchi L; Fathi AT; Brunner AM; Hasserjian RP; Nardi V
Histopathology; 2022 Oct; 81(4):496-510. PubMed ID: 35869818
[TBL] [Abstract][Full Text] [Related]
2. Immunohistochemistry screening for TP53 mutation in myeloid neoplasms in AZF-fixed bone marrow biopsies.
Yang G; Anderson Williams S; He F; He Y; McIntyre K; Beckman AK; Nelson AC; Yohe SL
Pathology; 2024 Apr; 56(3):404-412. PubMed ID: 38341302
[TBL] [Abstract][Full Text] [Related]
3. Combined Immunohistochemistry of PLK1, p21, and p53 for Predicting TP53 Status: An Independent Prognostic Factor of Breast Cancer.
Watanabe G; Ishida T; Furuta A; Takahashi S; Watanabe M; Nakata H; Kato S; Ishioka C; Ohuchi N
Am J Surg Pathol; 2015 Aug; 39(8):1026-34. PubMed ID: 26171916
[TBL] [Abstract][Full Text] [Related]
4. [Investigation for pathological interpretation criteria and its prognostic value for P53 expression in Chinese diffuse large B-cell lymphoma].
Shi YF; Gao ZF; Li XH; Guo LG; Zheng QL; Long MP; Deng LJ; Du TT; Jia L; Zhao W; Song XX; Li M
Zhonghua Xue Ye Xue Za Zhi; 2022 Dec; 43(12):1010-1015. PubMed ID: 36709106
[No Abstract] [Full Text] [Related]
5. TP53 mutations and protein immunopositivity may predict for poor outcome but also for trastuzumab benefit in patients with early breast cancer treated in the adjuvant setting.
Fountzilas G; Giannoulatou E; Alexopoulou Z; Zagouri F; Timotheadou E; Papadopoulou K; Lakis S; Bobos M; Poulios C; Sotiropoulou M; Lyberopoulou A; Gogas H; Pentheroudakis G; Pectasides D; Koutras A; Christodoulou C; Papandreou C; Samantas E; Papakostas P; Kosmidis P; Bafaloukos D; Karanikiotis C; Dimopoulos MA; Kotoula V
Oncotarget; 2016 May; 7(22):32731-53. PubMed ID: 27129168
[TBL] [Abstract][Full Text] [Related]
6. Refined criteria for p53 expression in ovarian mucinous tumours are highly concordant with TP53 mutation status, but p53 expression/TP53 status lack prognostic significance.
Dundr P; Hájková N; Kendall Bártů M; Cibula D; Drozenová J; Fabian P; Fadare O; Frühauf F; Hausnerová J; Hojný J; Laco J; Lax SF; Matěj R; Méhes G; Michálková R; Němejcová K; Singh N; Stolnicu S; Švajdler M; Zima T; McCluggage WG; Stružinská I
Pathology; 2023 Oct; 55(6):785-791. PubMed ID: 37500307
[TBL] [Abstract][Full Text] [Related]
7. Clinical significance of p53 protein expression and TP53 variation status in colorectal cancer.
Kim KM; Ahn AR; Park HS; Jang KY; Moon WS; Kang MJ; Ha GW; Lee MR; Chung MJ
BMC Cancer; 2022 Aug; 22(1):940. PubMed ID: 36045334
[TBL] [Abstract][Full Text] [Related]
8.
Thiel KW; Devor EJ; Filiaci VL; Mutch D; Moxley K; Alvarez Secord A; Tewari KS; McDonald ME; Mathews C; Cosgrove C; Dewdney S; Aghajanian C; Samuelson MI; Lankes HA; Soslow RA; Leslie KK
J Clin Oncol; 2022 Oct; 40(28):3289-3300. PubMed ID: 35658479
[TBL] [Abstract][Full Text] [Related]
9. [Clinical and prognostic values of TP53 mutation in patients with acute myeloid leukemia].
Zhang Y; Hu XX; Gao L; Ni X; Chen J; Chen L; Zhang WP; Yang JM; Wang JM
Zhonghua Xue Ye Xue Za Zhi; 2019 Nov; 40(11):932-938. PubMed ID: 31856443
[No Abstract] [Full Text] [Related]
10. Performance of the pattern-based interpretation of p53 immunohistochemistry as a surrogate for TP53 mutations in vulvar squamous cell carcinoma.
Kortekaas KE; Solleveld-Westerink N; Tessier-Cloutier B; Rutten TA; Poelgeest MIE; Gilks CB; Hoang LN; Bosse T
Histopathology; 2020 Jul; 77(1):92-99. PubMed ID: 32236967
[TBL] [Abstract][Full Text] [Related]
11. TP53 copy number and protein expression inform mutation status across risk categories in acute myeloid leukemia.
Tashakori M; Kadia T; Loghavi S; Daver N; Kanagal-Shamanna R; Pierce S; Sui D; Wei P; Khodakarami F; Tang Z; Routbort M; Bivins CA; Jabbour EJ; Medeiros LJ; Bhalla K; Kantarjian HM; Ravandi F; Khoury JD
Blood; 2022 Jul; 140(1):58-72. PubMed ID: 35390143
[TBL] [Abstract][Full Text] [Related]
12. p53 immunostaining cannot be used to predict TP53 mutations in gastric cancer: results from a large Central European cohort.
Schoop I; Maleki SS; Behrens HM; Krüger S; Haag J; Röcken C
Hum Pathol; 2020 Nov; 105():53-66. PubMed ID: 32971129
[TBL] [Abstract][Full Text] [Related]
13. TP53 mutation in patients with high-risk acute myeloid leukaemia treated with allogeneic haematopoietic stem cell transplantation.
Middeke JM; Herold S; Rücker-Braun E; Berdel WE; Stelljes M; Kaufmann M; Schäfer-Eckart K; Baldus CD; Stuhlmann R; Ho AD; Einsele H; Rösler W; Serve H; Hänel M; Sohlbach K; Klesse C; Mohr B; Heidenreich F; Stölzel F; Röllig C; Platzbecker U; Ehninger G; Bornhäuser M; Thiede C; Schetelig J;
Br J Haematol; 2016 Mar; 172(6):914-22. PubMed ID: 26771088
[TBL] [Abstract][Full Text] [Related]
14. p53 immunostaining pattern is a useful surrogate marker for TP53 gene mutations.
Sung YN; Kim D; Kim J
Diagn Pathol; 2022 Dec; 17(1):92. PubMed ID: 36471402
[TBL] [Abstract][Full Text] [Related]
15. Optimized p53 immunohistochemistry is an accurate predictor of
Köbel M; Piskorz AM; Lee S; Lui S; LePage C; Marass F; Rosenfeld N; Mes Masson AM; Brenton JD
J Pathol Clin Res; 2016 Oct; 2(4):247-258. PubMed ID: 27840695
[No Abstract] [Full Text] [Related]
16. p53 immunohistochemistry as an ancillary tool for rapid assessment of residual disease in TP53-mutated acute myeloid leukemia and myelodysplastic syndromes.
Brar N; Lawrence L; Fung E; Zehnder JL; Greenberg PL; Mannis GN; Zhang TY; Gratzinger D; Oak J; Silva O; Kurzer J; Tan B; Menke JR; Fernandez-Pol S
Am J Clin Pathol; 2024 Apr; ():. PubMed ID: 38643353
[TBL] [Abstract][Full Text] [Related]
17. p53 Immunohistochemical Staining and TP53 Gene Mutations in Endometrial Cancer: Does Null Pattern Correlate With Prognosis?
Sakamoto I; Kagami K; Nozaki T; Hirotsu Y; Amemiya K; Oyama T; Omata M
Am J Surg Pathol; 2023 Oct; 47(10):1144-1150. PubMed ID: 37528644
[TBL] [Abstract][Full Text] [Related]
18.
Yu R; Sun T; Zhang X; Li Z; Xu Y; Liu K; Shi Y; Wu X; Shao Y; Kong L
Onco Targets Ther; 2021; 14():4967-4978. PubMed ID: 34629881
[TBL] [Abstract][Full Text] [Related]
19. P53 mutation analysis of colorectal liver metastases: relation to actual survival, angiogenic status, and p53 overexpression.
de Jong KP; Gouw AS; Peeters PM; Bulthuis M; Menkema L; Porte RJ; Slooff MJ; van Goor H; van den Berg A
Clin Cancer Res; 2005 Jun; 11(11):4067-73. PubMed ID: 15930341
[TBL] [Abstract][Full Text] [Related]
20. Current status and new treatment approaches in TP53 mutated AML.
Hunter AM; Sallman DA
Best Pract Res Clin Haematol; 2019 Jun; 32(2):134-144. PubMed ID: 31203995
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
